论文部分内容阅读
血糖控制的良好与否决定了糖尿病透析患者的远期预后,而此类患者选用口服降糖药并非良策。由于尿毒症导致的胰岛素抵抗使得这部分患者胰岛素用量大大增加。罗格列酮作为改善胰岛素抵抗的新型降糖药物,其排泄不受肾功能影响,同时其抗炎作用可能对透析患者有益。香港研究者的研究表明,罗格列酮联合胰岛素可有效改善糖尿病腹膜透析患者胰岛素抵抗及炎症状态,这一结果发表在American Journal of Kidney Diseases杂志上。
Good blood glucose control determines the long-term prognosis of diabetic patients with dialysis, and such patients choose oral hypoglycemic agents are not good policy. Because of uremia caused by insulin resistance makes this part of the patient’s insulin dosage greatly increased. Rosiglitazone, a new hypoglycemic agent that improves insulin resistance, is not excreted by renal function, and its anti-inflammatory effects may be beneficial for dialysis patients. Researchers from Hong Kong have shown that rosiglitazone and insulin can effectively improve insulin resistance and inflammatory status in patients with diabetic peritoneal dialysis. This result was published in American Journal of Kidney Diseases.